SELECT METASTATIC BREAST CANCER DOSING AND ADMINISTRATION
Assessment of HER2 protein overexpression and HER2 gene amplification should be performed using FDA-approved tests specific for breast cancer by laboratories with demonstrated proficiency.1
To begin PERJETA and Herceptin® (trastuzumab) and docetaxel, patients must have HER2+ metastatic breast cancer (MBC), and not have previously received anti-HER2 therapy or chemotherapy for MBC.1
Please see the full Prescribing Information for complete dosing and administration, including dose considerations, dose modifications, preparation, storage, and handling. You can also download the PERJETA Dosing & Administration Guide.